



Formulary Change	#
New Exclusions for 2021	57
Number of Specialty Drugs	17
Positive Changes (add backs)	6
Member Impact %	1.4
Cost Impact %	3.1

Key Insights

- CVS will exclude 57 products from their formulary effective January 2021. This is expected to represent 2.1 percent impact to members and 3.3 percent impact on cost.
- Accu-Chek® test strips will be excluded and OneTouch® test strips will return as preferred after being removed just two years ago in 2019. Members will be transitioned back to OneTouch products and CVS will work with plan sponsors to minimize member disruption.
- Oracea®, doxycycline monohydrate used for the treatment of rosacea, will join Adderall®, Concerta® and Advair® on the Tier 1 strategy, which prefers the use of brand name drug over an equivalent generic. The brand drugs are available at a generic copay to the member.
- Seventeen formulary exclusions involve **specialty drugs**, which include coverage of the generic equivalent for Tecfidera® used for MS and Tracleer® used for pulmonary arterial hypertension (PAH). As well as coverage of Ziextenzo®, a biosimilar for Neulasta®. Neulasta and another Neulasta biosimilar, Udenyca®, are being removed.
- The highly rebatable **growth hormone drugs** will see changes with the removal of Humatrope®. Genotropin® and Norditropin® will be the preferred growth hormone products in 2021.
- CVS continues their focus on managing the **hyperinflationary drugs** with the removal of calcipotriene/betamethasone for which cost/claim exceeds \$1500.
- Trintellix® will remain as the only branded SSRI **antidepressant** with the removal of Paxil®, Paxil CR®, Pexeva® and Viibyrd®.
- Turing Pharmaceutical's drug Daraprim®, which can be considered the "poster-child" for price gauging, has a generic equivalent now available with a list price about half of that of Daraprim. CVS will remove the brand Daraprim.

**GET THE FORMULARY STRATEGY AND SUPPORT YOU NEED
FOR AN EVER-EVOLVING MARKET. CONTACT PSG TODAY!**